Anti-Cancer Drug Delivery Agents
Most investigated ways to deal with creating cell-based Anti-Cancer drug conveyance frameworks (DDSs) are the epitome of the medication into the cells, cell surface alteration, hereditary adjustment of cells to discharge wanted restorative proteins, and producing new biosynthetic frameworks. Cancer tropism of mesenchymal undifferentiated organisms (MSCs), as uncover in many examinations, can be fuse with confiscating designing with anticancer qualities to approve their usage in anticancer treatment. Moreover, MSCs can be loaded up with nanoparticles (NPs), obtain transport across the blood-cerebrum obstruction and collection of anticancer specialist at the growth site.
- Mesenchymal Undifferentiated Organisms (MSCs),
- Anticancer Treatment
Related Conference of Anti-Cancer Drug Delivery Agents
7th World Congress on Advanced Clinical Trials and Clinical Research
4th International Forum on Pharmacovigilance and Regulatory Affairs
30th International Conference on Neuropharmacology and Neurochemistry
Anti-Cancer Drug Delivery Agents Conference Speakers
Recommended Sessions
- Advanced Drug Delivery Systems
- Anti-Cancer Drug Delivery Agents
- Cellular Targeting and Intracellular Delivery
- Drug Delivery Technologies
- Drug Delivery through Blood-Brain Barrier (BBB)
- Drug Discovery and Development
- Drug Targeting and Design
- Nanotechnology for better Drug Deliverability
- Novel Drug Delivery
- Peptides and Protein Drug Delivery
- Pharmaceutical Formulation Technologies
- Routes of Drug Administration
- Therapeutic Drug Carrier Systems
- Vaccine Drug Delivery Systems
Related Journals
Are you interested in
- Adaptive Trial Models - Clinical Trials Congress 2025 (Spain)
- Advanced Data Analytics - Clinical Trials Congress 2025 (Spain)
- Adverse Event Reporting through Mobile Health Tools - Euro Pharmacovigilance 2025 (Spain)
- AI in Clinical Research - Clinical Trials Congress 2025 (Spain)
- AI-Driven Signal Detection and Data Mining - Euro Pharmacovigilance 2025 (Spain)
- AI-Powered Pharmacovigilance - Clinical Trials Congress 2025 (Spain)
- Artificial Intelligence in Neuropharmacological Drug Discovery - Neuropharmaceutics 2026 (Indonesia)
- Automation in Case Processing and Reporting - Euro Pharmacovigilance 2025 (Spain)
- Blockchain Applications - Clinical Trials Congress 2025 (Spain)
- Blockchain Applications in Regulatory Data Integrity - Euro Pharmacovigilance 2025 (Spain)
- Blood-Brain Barrier Pharmacology and Drug Delivery - Neuropharmaceutics 2026 (Indonesia)
- Brain-Computer Interfaces and Neurochemical Modulation - Neuropharmaceutics 2026 (Indonesia)
- Clinical Supply Chain Innovation - Clinical Trials Congress 2025 (Spain)
- Computational and Systems Neuropharmacology - Neuropharmaceutics 2026 (Indonesia)
- Data Integrity & Compliance - Clinical Trials Congress 2025 (Spain)
- Decentralized Trials - Clinical Trials Congress 2025 (Spain)
- Digital Biomarkers and Neurochemical Monitoring Technologies - Neuropharmaceutics 2026 (Indonesia)
- Digital Therapeutics Trials - Clinical Trials Congress 2025 (Spain)
- Digital Transformation in Drug Safety Operations - Euro Pharmacovigilance 2025 (Spain)
- Diversity in Enrollment - Clinical Trials Congress 2025 (Spain)
- eConsent & Retention Tools - Clinical Trials Congress 2025 (Spain)
- eSource & EDC Systems - Clinical Trials Congress 2025 (Spain)
- Ethics and Legal Challenges in Drug Safety Surveillance - Euro Pharmacovigilance 2025 (Spain)
- Global Harmonization of Regulatory Frameworks - Euro Pharmacovigilance 2025 (Spain)
- Global Regulatory Landscape - Clinical Trials Congress 2025 (Spain)
- Global Signal Management Systems and Standards - Euro Pharmacovigilance 2025 (Spain)
- Inspection Readiness and Audit Best Practices - Euro Pharmacovigilance 2025 (Spain)
- Integrating Neurochemistry with Computational Brain Modeling - Neuropharmaceutics 2026 (Indonesia)
- Integration of PV with Quality and Regulatory Affairs - Euro Pharmacovigilance 2025 (Spain)
- Machine Learning Models in Neurochemical Data Analysis - Neuropharmaceutics 2026 (Indonesia)
- Managing Safety Data in Multi-Region Submissions - Euro Pharmacovigilance 2025 (Spain)
- Master Protocol Strategies - Clinical Trials Congress 2025 (Spain)
- Molecular Mechanisms in Neuropharmacology - Neuropharmaceutics 2026 (Indonesia)
- Neurochemical Basis of Epilepsy and Anticonvulsant Pharmacology - Neuropharmaceutics 2026 (Indonesia)
- Neurochemical Basis of Mood Disorders and Emotional Regulation - Neuropharmaceutics 2026 (Indonesia)
- Neurochemical Big Data and Cloud-Based Pharmacology Platforms - Neuropharmaceutics 2026 (Indonesia)
- Neurochemical Biosensors and Real-Time Brain Monitoring - Neuropharmaceutics 2026 (Indonesia)
- Neurochemical Mechanisms in Neurodegenerative Disorders - Neuropharmaceutics 2026 (Indonesia)
- Neurochemical Signaling and Synaptic Transmission - Neuropharmaceutics 2026 (Indonesia)
- Neurochemistry of Addiction and Reward Pathways - Neuropharmaceutics 2026 (Indonesia)
- Neurochemistry of Neuroendocrine Regulation - Neuropharmaceutics 2026 (Indonesia)
- Neurochemistry of Psychiatric and Mood Disorders - Neuropharmaceutics 2026 (Indonesia)
- Neuroimaging Analytics and Computational Mapping of Brain Chemistry - Neuropharmaceutics 2026 (Indonesia)
- Neuroinflammation and Pharmacological Modulation - Neuropharmaceutics 2026 (Indonesia)
- Neuroinformatics and Computational Neuropharmacology - Neuropharmaceutics 2026 (Indonesia)
- Neuropharmacological Approaches to Pain and Analgesia - Neuropharmaceutics 2026 (Indonesia)
- Neuropharmacological Approaches to Pain Modulation and Analgesia - Neuropharmaceutics 2026 (Indonesia)
- Neuropharmacology of Addiction and Substance Abuse - Neuropharmaceutics 2026 (Indonesia)
- Neuropharmacology of Cognitive Function and Memory - Neuropharmaceutics 2026 (Indonesia)
- Neuropharmacology of Neurodegenerative Disorders - Neuropharmaceutics 2026 (Indonesia)
- Neuropharmacology of Neurodevelopmental and Autism Spectrum Disorders - Neuropharmaceutics 2026 (Indonesia)
- Neuropharmacology of Neuroplasticity and Neural Regeneration - Neuropharmaceutics 2026 (Indonesia)
- Neurotransmitter Receptors and Signal Transduction - Neuropharmaceutics 2026 (Indonesia)
- Patient-Centric Designs - Clinical Trials Congress 2025 (Spain)
- Patient-Centric Pharmacovigilance Strategies - Euro Pharmacovigilance 2025 (Spain)
- Pharmacovigilance Compliance in Clinical Trials - Euro Pharmacovigilance 2025 (Spain)
- Pharmacovigilance in Accelerated Drug Approvals - Euro Pharmacovigilance 2025 (Spain)
- Pharmacovigilance in Gene and Cell Therapies - Euro Pharmacovigilance 2025 (Spain)
- Pharmacovigilance Outsourcing and Vendor Oversight - Euro Pharmacovigilance 2025 (Spain)
- Precision Neuropharmacology through Artificial Intelligence and Genomic Profiling - Neuropharmaceutics 2026 (Indonesia)
- Real-World Evidence in Post-Marketing Surveillance - Euro Pharmacovigilance 2025 (Spain)
- Real-World Evidence Integration - Clinical Trials Congress 2025 (Spain)
- Risk Management Planning and Benefit-Risk Assessment - Euro Pharmacovigilance 2025 (Spain)
- Risk-Based Monitoring - Clinical Trials Congress 2025 (Spain)
- Safety Labeling Changes and Regulatory Communication - Euro Pharmacovigilance 2025 (Spain)
- Safety Monitoring of Biologics and Biosimilars - Euro Pharmacovigilance 2025 (Spain)
- Synthetic Control Arms - Clinical Trials Congress 2025 (Spain)
- Virtual Drug Screening and Molecular Docking in Neuropharmacology - Neuropharmaceutics 2026 (Indonesia)
- Virtual Trial Platforms - Clinical Trials Congress 2025 (Spain)
- Wearables & Remote Monitoring - Clinical Trials Congress 2025 (Spain)
